| Name | Title | Contact Details |
|---|
Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer.
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.
Andau Medical is a Canadian Medical Device and Dental Device company focused on providing the market with quality technologies that improve patient outcomes and enhance the clinical experience in delivering exceptional patient care.
ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.